ATE301721T1 - In vivo herstellung von replicativen molekülen - Google Patents

In vivo herstellung von replicativen molekülen

Info

Publication number
ATE301721T1
ATE301721T1 AT97925133T AT97925133T ATE301721T1 AT E301721 T1 ATE301721 T1 AT E301721T1 AT 97925133 T AT97925133 T AT 97925133T AT 97925133 T AT97925133 T AT 97925133T AT E301721 T1 ATE301721 T1 AT E301721T1
Authority
AT
Austria
Prior art keywords
vivo production
molecules
replicative
replicative molecules
situ
Prior art date
Application number
AT97925133T
Other languages
English (en)
Inventor
Michel Perricaudet
Patrice Yeh
Helene Leblois-Prehaud
Original Assignee
Gencell Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gencell Sa filed Critical Gencell Sa
Application granted granted Critical
Publication of ATE301721T1 publication Critical patent/ATE301721T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
AT97925133T 1996-06-12 1997-05-23 In vivo herstellung von replicativen molekülen ATE301721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9607273A FR2749857B1 (fr) 1996-06-12 1996-06-12 Generation de molecules replicatives in vivo
PCT/FR1997/000914 WO1997047757A1 (fr) 1996-06-12 1997-05-23 Generation de molecules replicatives in vivo

Publications (1)

Publication Number Publication Date
ATE301721T1 true ATE301721T1 (de) 2005-08-15

Family

ID=9492965

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97925133T ATE301721T1 (de) 1996-06-12 1997-05-23 In vivo herstellung von replicativen molekülen

Country Status (18)

Country Link
US (1) US6630322B1 (de)
EP (1) EP0906443B1 (de)
JP (1) JP2000511779A (de)
AT (1) ATE301721T1 (de)
AU (1) AU726442B2 (de)
BR (1) BR9709700A (de)
CA (1) CA2257916A1 (de)
CZ (1) CZ296600B6 (de)
DE (1) DE69733948T2 (de)
DK (1) DK0906443T3 (de)
ES (1) ES2248849T3 (de)
FR (1) FR2749857B1 (de)
HU (1) HU224175B1 (de)
IL (1) IL127430A0 (de)
NO (1) NO985739D0 (de)
SK (1) SK169898A3 (de)
WO (1) WO1997047757A1 (de)
ZA (1) ZA975134B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1317560A4 (de) * 2000-09-08 2005-10-05 Gen Hospital Corp Sich selbst neuordnende dna vektoren(18.03.02)
AU2002325346A1 (en) 2001-07-05 2003-01-21 Aventis Pharma S.A. Method of administration of a gene of interest to the heart and vasculature
US7164056B2 (en) 2002-05-03 2007-01-16 Pioneer Hi-Bred International, Inc. Gene targeting using replicating DNA molecules
JP2012508591A (ja) * 2008-11-14 2012-04-12 ライフ テクノロジーズ コーポレーション 細胞を操作するための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5834256A (en) * 1993-06-11 1998-11-10 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6120764A (en) * 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
EP0632054A1 (de) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Regulation stellenspezifischer Rekombination mittels stellungsspezifischer Rekombinase/Kernrezeptor-Fusionsproteine
JP4216350B2 (ja) * 1994-09-19 2009-01-28 大日本住友製薬株式会社 動物細胞感染用の組換えｄｎａウイルスベクター
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
WO1997025446A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors

Also Published As

Publication number Publication date
US6630322B1 (en) 2003-10-07
CZ296600B6 (cs) 2006-04-12
ES2248849T3 (es) 2006-03-16
FR2749857B1 (fr) 1998-08-14
NO985739L (no) 1998-12-08
NO985739D0 (no) 1998-12-08
DE69733948T2 (de) 2006-06-08
HUP9902585A2 (hu) 1999-11-29
AU3037797A (en) 1998-01-07
BR9709700A (pt) 1999-08-10
CZ402398A3 (cs) 1999-03-17
DK0906443T3 (da) 2005-12-19
JP2000511779A (ja) 2000-09-12
ZA975134B (en) 1997-12-31
EP0906443A1 (de) 1999-04-07
WO1997047757A1 (fr) 1997-12-18
AU726442B2 (en) 2000-11-09
HUP9902585A3 (en) 2001-11-28
IL127430A0 (en) 1999-10-28
EP0906443B1 (de) 2005-08-10
SK169898A3 (en) 1999-07-12
DE69733948D1 (de) 2005-09-15
HU224175B1 (hu) 2005-06-28
CA2257916A1 (fr) 1997-12-18
FR2749857A1 (fr) 1997-12-19

Similar Documents

Publication Publication Date Title
DE69525369D1 (de) Kontinuierliches polymerisationverfahren von polyamiden
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
EP0757717A4 (de) Papillomavirus vakzine
DE69730218D1 (de) Fusogene liposomen
ATE481480T1 (de) Methoden und zusammensetzungen zur herstellung von polypeptiden
DK0939767T3 (da) Procin faktor VIII og hybrider deraf
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
DE60126933D1 (de) Verfahren zur fermentativen herstellung von l-threonine
NO20002504L (no) Adenovirusvektorer og fremgangsmÕte for Õ redusere homologe rekombinasjonsfenomener
DE69934998D1 (de) Antisense modulation der expression von integrin alpha 4
DE69328025D1 (de) Dorsalgewebe beeinflussender faktor und zusammensetzungen
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
NO20003146D0 (no) Ketonperoksyd-derivater, deres fremstilling og anvendelse
ATE210631T1 (de) Verfahren zur herstellung von iohexol
DE69902714D1 (de) Verfahren zur Herstellung von Naturkautschuk und damit erhaltener Naturkautschuk
ATE329055T1 (de) Methode zur erstellung von genexpressionsprofilen
ATE286908T1 (de) Gewebespezifische expression des retinoblastoma- proteins
DE69726602D1 (en) Hepatitis b inhibitoren
DE59611293D1 (de) Protein mit dnase-aktivität
DE69531678D1 (de) Rekombinatie viren,ihre herstellung und ihre verwendung in der gentherapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906443

Country of ref document: EP

REN Ceased due to non-payment of the annual fee